Follow the Pundits
Tag: investing
🏦 Alkami Technology (ALKT): The “Picks and Shovels” of Digital Banking
Alkami Technology (ALKT) isn’t a bank — it’s the digital engine powering modern banking for millions of users. After a brutal fintech reset, General Atlantic just bought another $34M worth of shares. Coincidence… or conviction?
Sweetgreen (SG): 90% Down—Turnaround or Trap? 🥗📉
Sweetgreen looks fresh on the menu—but the stock tells a different story. With high short interest, insider buying, and weak fundamentals, SG is a high-risk contrarian bet investors should approach carefully.
NVIDIA (NVDA) Stock Analysis 2026: Is the AI King Still Investable? 🚀
NVIDIA isn’t just riding the AI wave—it is the wave. But at $172, is NVDA still a smart play, or are investors dancing a little too close to perfection?
Alfred Lin of Sequoia Capital Buys $100 Million Worth of DoorDash Stock. Will The Shares Deliver?
When Sequoia’s Alfred Lin drops a $100M insider buy on DoorDash, investors pay attention. DASH is growing fast, expanding globally, and courting robots — but is the stock about to deliver… or disappoint?
Amazon Is ValueAct Holdings’ Top Holding. Should You Buy?
ValueAct didn’t nibble—Amazon is its top holding. Under the hood: AWS growth, retail media margins, and AI making robots, delivery, and dev tools smarter. Not cheap—but quality compounding can justify the tag. Read our Quick Take, risks box, and how to buy dips with a cool head.
Institutions & Hedge Funds Are Buying and The Stock Is on a Tear. Will Robinhood (HOOD) Keep Stealing the Show?
Robinhood isn’t just stealing trades — it’s stealing headlines. With institutions buying, hedge funds betting, and analysts raising targets, HOOD is on a tear. But can the show go on? 🎟️🔥
OpenAI Likes Etsy. Renaissance, Elliott, and AQR Do Too. Should You?
Etsy’s stock soared after OpenAI’s “Buy it in ChatGPT” debut—plus Wall Street whales are piling in. Here’s why Etsy might be a handmade bargain with AI sparkle.
Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?
When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.
GAMCO Investors Is Full of Winners — Except Paramount (PARA): Why This One Dud Might Finally Shine
Is Paramount Global a value trap—or a future media giant in disguise? Streaming growth, big-name backers like GAMCO and Vanguard, and Apple buyout rumors make this drama worth watching. 🍿🎥
Bausch Health: Paulson Doubles Down, Stock Breaks Out, Recovery Accelerates
Bausch Health ($BHC) is back in the spotlight as legendary investor John Paulson adds millions more in shares, fueling a breakout rally. With Q2 earnings showing revenue growth, profit rebound, and debt repayment plans, could BHC be staging its long-awaited comeback?